Plant Name: Valeriana jatamansi
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 4.763E-13 | 2.593E-09 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 4.763E-13 | 2.593E-09 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.193E-11 | 3.711E-08 | HTR1B, HTR1D, HTR2A, HTR2C |
| BP | GO:0023052; signaling | GO:0007268; chemical synaptic transmission | 1.807E-07 | 2.918E-04 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 2.412E-07 | 2.918E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 2.412E-07 | 2.918E-04 | HTR2A, HTR2C |
| BP | Unclassified; | GO:0042310; vasoconstriction | 3.625E-07 | 4.155E-04 | HTR1B, HTR1D, HTR2A |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 2.410E-06 | 2.099E-03 | HTR2A, HTR2C |
| BP | GO:0050896; response to stimulus | GO:0042221; response to chemical | 2.617E-06 | 2.192E-03 | CYP1A2, HTR1B, HTR1D, HTR2A, HTR2C, LMNA, MPO, TSHR |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 4.095E-06 | 3.302E-03 | HTR1B, HTR1D, HTR2A |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.244E-05 | 8.738E-03 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.240E-09 | 1.743E-08 | HTR6; HTR1D; HTR1B; HTR2C; HTR2A |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.341E-09 | 1.743E-08 | HTR6; HTR1D; HTR1B; HTR2C; HTR2A; TSHR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.906E-06 | 1.461E-05 | HTR6; HTR1D; HTR1B; TSHR |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 8.213E-05 | 4.271E-04 | HTR6; HTR2C; HTR2A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.602E-04 | 1.886E-03 | CYP2A6; CYP1A2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.185E-04 | 1.886E-03 | CYP2A6; CYP1A2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.802E-04 | 1.886E-03 | CYP2A6; CYP1A2 |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 7.493E-04 | 1.948E-03 | HTR1D; HTR1B |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.042E-03 | 2.259E-03 | HTR2C; HTR2A |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 8.418E-04 | 1.990E-03 | HTR2C; HTR2A |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.315E-04 | 1.948E-03 | CYP2A6; CYP1A2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.248E-06 | 1.461E-05 | CYP2A6; CYP1A2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.983E-02 | 3.682E-02 | CYP1A2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.766E-02 | 4.136E-02 | TSHR |
| hsa05320 | Autoimmune thyroid disease_Homo sapiens_hsa05320 | 2.619E-02 | 4.136E-02 | TSHR |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.277E-02 | 3.947E-02 | CYP2A6 |
| hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 3.495E-02 | 4.732E-02 | TSHR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.441E-02 | 2.882E-02 | CYP1A2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.863E-02 | 4.136E-02 | CYP1A2 |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC)_Homo sapiens_hsa05412 | 3.640E-02 | 4.732E-02 | LMNA |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR1B; HTR1D; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR1B; HTR2A; HTR2C; HTR6; HTR6 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; HTR6; HTR6 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1B; HTR1D; HTR2A; HTR2C |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D |
| NA: NA | Addiction | NA | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2A; HTR2A; HTR2C; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1D |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1B; HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1D; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR1B; HTR1D; HTR2C; HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR2C; HTR6 |
| NA: NA | Primary insomnia | NA | HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |